The increase will take place over the seven major markets (7MM), the U.S., France, Germany, Italy, Spain, the UK, and Japan.
A recent report attributes this rise to poor infection control and a subsequent increase in antibiotic-resistant bacteria across these markets, combined with underlying demographic changes.
Initially, MRSA infections were typically acquired in a healthcare environment, however in more recent years community-acquired MRSA infections have predominated.
According to GlobalData epidemiologists, there were 552,000 community-acquired hospitalized incident cases of MRSA in 2023 and 162,000 healthcare-acquired cases in the 7MM.
Anna Moody, epidemiologist at GlobalData, said: “Infection control in healthcare settings has vastly improved across the 7MM over the past decade; however, the appropriate adjustment of hygiene practices in community settings lacks consideration for the presence of antibiotic-resistant bacteria, like MRSA.
“This explains why the number of community-acquired hospitalized incident cases of MRSA is higher than healthcare-acquired cases.”
Across the 7MM, community-acquired cases of MRSA are expected to increase to 612,000 by 2033, at an average growth rate of 1.09%, whilst the healthcare-acquired cases will increase to 179,000 by 2033, at an average growth rate of 1.05%.
Moody concludes: “As the incidence of antibiotic-resistant bacteria increases, there should be an improved focus on infection control, both in and out of healthcare settings, and practitioners should avoid inappropriate and over-use of antibiotics where possible.”